

MelNet update

20 October 2023

Dermoscopy of Non-Melanoma Skin Cancer online series | 4 October – 22 November 2023

Our *Dermoscopy of non-melanoma skin cancer* online series is now in full swing.

If you're interested in improving your ability to recognise and detect non-melanoma skin cancers, [you can still register!](#) We will provide you with previous episodes and you can go through the content at your own pace ahead of the live discussion forum on 22 November.

The cost is \$80 (including GST).

If you have registered for this course but haven't received Episodes 1, 2 and 3, please [contact us](#).

This series has been endorsed by RNZCGP for up to 4.5 CME credits for Continuing Professional Development (CPD) purposes and has been approved in the RACS CPD Program for 5 points in Educational Activities. Nurses will be provided with a certificate of attendance as evidence for their professional development portfolio.

[Find out more](#) [Register now](#)

Thank you to our generous sponsors



NON-MELANOMA SKIN CANCER DERMOSCOPY

An online series hosted by MelNet

Dermoscopy education delivered right to your inbox


Improve your understanding of the clinical and dermatoscopic characteristics of non-melanoma skin cancers and increase your ability to recognise and detect these cancers early.

For all those involved in the opportunistic detection of skin cancer. The course includes 7 weekly emails containing a video and other supporting educational material, plus a one hour live online discussion forum.



4 October - 22 November 2023

\$80 including GST | Endorsed for up to 5 CME credits

Visit www.melnet.org.nz to register



Kindly supported by



REMINDER MelNet AGM | 28 November 2023

The MelNet AGM will be held via Zoom from 7.30 – 8.00 pm on Tuesday 28 November 2023.

Members are invited to submit nominations for the Executive Committee in writing to the [MelNet Chief Executive](#) no later than 5.00 pm Tuesday 14 November 2023. These should include the nominee's name, a 200-word biography and the signatures of two members.

According to the MelNet rules, the Committee shall comprise at least eight and no more than 15 members, with occupations that span the continuum. Members who will be serving the second year of their two-year term have general practice, pathology, dermatology, oncology, research and surgical experience. Up to nine additional

members can be elected to the committee at the AGM. Preference will be given to those with expertise in plastic surgery, primary prevention and nursing.

Members are also invited to submit remits or other matters to be considered at the AGM to the [MelNet Chief Executive](#) no later than 5.00pm Tuesday 14 November 2023.

Please join the AGM via this link: <https://us02web.zoom.us/j/4453635635> or email the [MelNet Chief Executive for a calendar invitation](#).

We look forward to seeing you online.

What would you like to see in MelNet's 2024 work programme?

With the end of the year fast approaching, we are starting to look ahead to our work programme for 2024. If you have any suggestions on what you'd like us to deliver next year, [we'd love to hear your thoughts](#).

Melanoma Research and Therapy Special Interest Group meeting | 21 September 2023

It was fantastic to hold the latest Melanoma Research and Therapy Special Interest Group meeting as part of the NZ Society of Oncology conference in Napier. Thank you to those who attended.

Highly interesting and informative presentations led to productive cross-discipline discussions and connections.

Topics discussed were:

- Adjuvant and neo-adjuvant therapy and contemporary melanoma surgery
- Real-world outcomes of immunotherapy for melanoma brain metastases in New Zealand



Highlights from the meeting are available on the [MelNet website](#).

Third edition of Quality Statements to Guide Melanoma Diagnosis and Treatment in NZ now available

In case you missed it – the third edition of the '*Quality Statements to Guide Melanoma Diagnosis and Treatment in New Zealand*' is now available on the [MelNet website](#). Key changes to clinical content are noted in Appendix 5 of the document (pg 90 - 94). We encourage you to read the Quality Statements and share the document widely in your networks.

In the media

Melanoma immunotherapy recruits for clinical trial

A global melanoma immunotherapy trial is set to get underway in New Zealand. This month, recruitment begins for a clinical trial of an INT (Individualised Neoantigen Therapy). The therapy, used in combination with Keytruda, is personalised to each patient, based on their tumour's unique genetic mutations.

The Phase 3 clinical trial will recruit patients who have had melanomas surgically removed but are ineligible for the Pharmac funded Keytruda.

[Read the article](#)

Diagnosis and management of subungual melanoma

Diagnosing subungual melanoma can be a challenge, often resulting in poor outcomes for patients. Melanoma Institute Australia has developed a new educational video on the diagnosis and management of subungual melanoma, discussing:

- how subungual melanoma differs from cutaneous melanoma
- the pitfalls in the pathological assessment of subungual biopsies and how these can be avoided
- morphological differential diagnoses of longitudinal melanonychia, erythronychia and pachyonychia
- biopsy and surgical management of subungual melanoma.



[Watch now](#) through the MIA Education Portal (free log in required)

Dermatoscopic pitfalls in differentiating Spitz naevi from melanoma

Prof Giuseppe Argenziano explores the dermatoscopic pitfalls in differentiating Spitz naevi from cutaneous melanoma, highlighting studies and patient cases in which malignant melanoma mimicked the dermatoscopic and clinical characteristics of benign Spitzoid lesions.

[Watch now](#) on the HealthCert Blog




Upcoming opportunities and events



SITC 2023 provides a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy. The Annual Meeting consists of cutting-edge research presentations by experts in the field, oral and poster abstract presentations and ample opportunity for structured and informal discussions, including important networking opportunities.

[Find out more](#)



Hybrid event: Geneva, Switzerland and online

The global meeting offers an advanced educational programme and the latest scientific developments in this promising field. From the basics of immunotherapies to the latest research results; from understanding different treatment options to the management of toxicities and interpretation of new data, the ESMO Immuno-Oncology Congress will cater to the diverse needs of oncology stakeholders with an interest in this topical field of cancer treatment.

[Find out more](#)

Other upcoming opportunities and events

November and December	ONLINE courses starting ANYTIME
<p>Dermoscopy of non-melanoma skin cancer online series 4 October - 22 November 2023 Online Find out more</p> <p>Skin Cancer Medicine Practical Workshop Skin Cancer Surgery Practical Workshop 25 November 2023 Perth, Australia Find out more</p> <p>Advanced Skin Cancer Medicine Practical Workshop Complex Skin Cancer Surgery Practical Workshop 26 November 2023 Perth, Australia Find out more</p> <p>Professional Diploma of Skin Cancer Surgery 26 November 2023 Perth, Australia Find out more</p> <p>MelNet AGM 28 November 2023 Online Find out more</p> <p>For more events see the MelNet events calendar</p>	<p>Certificate of Dermoscopy Aimed at beginners to advanced in the field of dermoscopy and skin cancer. <i>Provider:</i> Skin Cancer Symposiums</p> <p>Introduction to Skin Cancer Introduction to the fundamentals of skin cancer medicine. <i>Provider:</i> Skin Cancer College Australasia</p> <p>Skin Cancer Medicine Acquire introductory to advanced skin cancer diagnosis and management knowledge. Some courses offer an optional practical workshop. <i>Provider:</i> HealthCert</p> <p>Skin Cancer Surgery Acquire introductory to advanced skin cancer surgery skills. Some courses offer an optional practical workshop. <i>Provider:</i> HealthCert</p> <p>Dermoscopy Improve diagnostic performance and clinical management of skin lesions by using dermoscopy. <i>Provider:</i> HealthCert</p> <p>Advanced Certificate of Dermoscopy for Dermatology Explores applications of dermoscopy in diagnosing skin and hair conditions commonly seen in primary care. <i>Provider:</i> HealthCert</p> <p>Advanced Certificate of Histopathology for Dermoscopy Comprehensive guide to the principles of dermatopathology. <i>Provider:</i> HealthCert</p> <p>Certificate of Case Management: Dermoscopy Improve diagnostic accuracy using dermoscopy. <i>Provider:</i> HealthCert</p>

Recent MelNet website postings

Below is a selection of recent **news postings** on the MelNet website. Please visit the [website](#) to view all the latest news items.

[Melanoma prevention programme using genomic risk information likely a cost-effective strategy](#)

[Genetic features of patients with mucosal melanoma may offer potential for targeted therapies](#)

[Larger perceived reduction of non-melanoma skin cancers attributed to nicotinamide is associated with increased oral nicotinamide use](#)

[PIVOT IO 001 study: No additional clinical benefit of BEMPEG plus NIVO combination therapy versus NIVO monotherapy for previously untreated unresectable or metastatic melanoma](#)

[Community pharmacies have potential to be change agents in skin cancer prevention](#)

[Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma](#)

[Squamous cell carcinoma in situ: Electrodesiccation and curettage allows for high 5-year cure rate across broad range of anatomic sites](#)

[Similar local recurrence and survival in patients with T1 radial growth phase melanoma on head and neck treated with 5 or 10 mm margins](#)

[Primary resistance to PD-1 blockade therapy can be reversed in some patients with combination of CTLA-4 and PD-1 blockade](#)

[Personalized and tumor-informed longitudinal ctDNA monitoring is a valuable prognostic and predictive tool for advanced melanoma](#)

[Nivolumab and relatlimab: Manageable safety profile, durable clinical activity in proportion of patients with heavily pretreated advanced melanoma with prior progression on anti-PD-\(L\)1-containing regimens](#)



Support our work. Donate to MelNet



Join us on facebook